301 related articles for article (PubMed ID: 28483388)
1. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease.
Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P
Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388
[No Abstract] [Full Text] [Related]
2. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
3. Lack of central and peripheral nervous system synuclein pathology in R1441G
Vilas D; Gelpi E; Aldecoa I; Grau O; Rodriguez-Diehl R; Jaumà S; Martí MJ; Tolosa E
J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):832-833. PubMed ID: 30054313
[No Abstract] [Full Text] [Related]
4. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Henderson MX; Peng C; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
[TBL] [Abstract][Full Text] [Related]
7. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
[TBL] [Abstract][Full Text] [Related]
8. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
[TBL] [Abstract][Full Text] [Related]
9. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
10. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons.
Qing X; Walter J; Jarazo J; Arias-Fuenzalida J; Hillje AL; Schwamborn JC
Stem Cell Res; 2017 Oct; 24():44-50. PubMed ID: 28826027
[TBL] [Abstract][Full Text] [Related]
12. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
[TBL] [Abstract][Full Text] [Related]
13. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M;
Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656
[TBL] [Abstract][Full Text] [Related]
14. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
Novello S; Arcuri L; Dovero S; Dutheil N; Shimshek DR; Bezard E; Morari M
Neurobiol Dis; 2018 Dec; 120():21-33. PubMed ID: 30172844
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.
Gomez A; Ferrer I
Acta Neuropathol; 2010 Aug; 120(2):155-67. PubMed ID: 20232069
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
eNeuro; 2017; 4(2):. PubMed ID: 28321439
[TBL] [Abstract][Full Text] [Related]
18. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
19. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
Vermilyea SC; Emborg ME
Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]